Clinical trials
Phase 1 Gastrointestinal Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 6 |
| Completed | 5 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 2 |
| Affiliated Hospital to Academy of Military Medical Sciences | 1 |
| Beijing GoBroad Hospital | 1 |
| Central South University | 1 |
| Chinese Academy of Medical Sciences | 1 |
| Curegenix Inc. | 1 |
| IDRX, Inc., a wholly owned subsidiary of GSK, LLC | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Peking Union Medical College Hospital | 1 |
| Peking University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gastrointestinal Neoplasms | 17 |
| Breast Neoplasms | 3 |
| Lung Neoplasms | 3 |
| Carcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Stomach Neoplasms | 2 |
| Bile Duct Neoplasms | 1 |
| Brain Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.